TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial.
Bruno Valentin SinnDenise TreueUlrich KeilholzFrederik DammRosa B SchmuckPhilipp LohneisFrederick KlauschenJana K StrieflerMarcus BahraHendrik BläkerSven BischoffUwe PelzerHelmut OettleHanno RiessJan BudcziesCarsten DenkertPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
In CONKO-001, the benefit from adjuvant gemcitabine was confined to the TP53mut patient group. This potentially clinical relevant observation needs to be confirmed in independent prospective studies. The sensitivity of TP53mut PDAC to gemcitabine in CONKO-001 provides a lead for further mechanistic investigations.